Clinical Trial Update: Case-Control Viramune (Nevirapine) Toxicogenomics Study

View source ↗

Summary

A completed case-control toxicogenomics study evaluating Nevirapine (Viramune) in HIV infection. The study appears to be sponsored by Boehringer Ingelheim.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Viramune (Nevirapine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Status: COMPLETED